Financial Performance - Zhejiang Garden Bio-chemical High-tech Co., Ltd. reported a total revenue of CNY 1.2 billion for the year 2021, representing a year-on-year growth of 15%[22] - The company achieved a net profit of CNY 300 million in 2021, which is an increase of 20% compared to the previous year[22] - The company's operating revenue for 2021 was ¥1,117,099,893.11, representing a 69.40% increase compared to the adjusted revenue of ¥659,437,443.09 in 2020[29] - The net profit attributable to shareholders for 2021 was ¥479,829,624.81, an increase of 82.29% from the adjusted net profit of ¥263,216,164.87 in 2020[29] - The net cash flow from operating activities for 2021 was ¥504,029,922.29, which is a 17.93% increase compared to ¥427,409,340.96 in 2020[29] - The basic earnings per share for 2021 was ¥0.88, up 69.23% from ¥0.52 in 2020[29] - The net profit for 2021 was 510.01 million yuan, reflecting a significant increase of 95.69% year-on-year[47] - The company reported a decrease in raw material costs in the pharmaceutical sector by 13.49% year-on-year[87] Market Expansion and Strategy - User data indicated a 25% increase in the number of active customers, reaching 500,000 by the end of 2021[22] - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share in the region by 2025[22] - The company completed the acquisition of 100% equity in Huayuan Pharmaceutical in November 2021, expanding its operations into the pharmaceutical manufacturing sector[44] - The company has signed a 15-year procurement agreement with DSM for 7-dehydrocholesterol, enhancing its supply chain stability[47] - The company aims to achieve a gross margin of 35% in 2022, up from 30% in 2021[22] - The company is transitioning from generic drugs to high-end generics with high technical barriers, focusing on chronic disease areas such as cardiovascular and neurological systems[69] Research and Development - The company has allocated CNY 50 million for research and development in innovative drug formulations for the upcoming fiscal year[22] - The company has made significant progress in new product development, obtaining drug registration certificates for five products, including three specifications of escitalopram oxalate tablets and two injectable drugs[60] - The total R&D investment in 2021 was ¥68,545,827.04, accounting for 6.14% of operating revenue, a decrease from 7.97% in 2020[100] - The number of R&D personnel increased by 13.22% from 121 in 2020 to 137 in 2021[100] - The company is currently in the process of developing several new products, with ongoing evaluations and approvals, indicating a focus on expanding its product line and market competitiveness[98] Operational Efficiency - A strategic acquisition of a local competitor is anticipated to enhance production capacity by 40%[22] - The company is set to commence trial production at the Jinxin Technology Park by the end of June 2022, following the completion of equipment installation[47] - The company has established a nationwide sales network primarily targeting hospitals, utilizing a "distribution + academic promotion" sales model[58] - The production capacity of the vitamin D3 segment at the Dongyang production base is fully utilized, meeting customer order demands, with a long-term procurement agreement signed with DSM for 7-dehydrocholesterol products[59] Governance and Compliance - The company maintains an independent operational structure, with no financial guarantees provided to the controlling shareholder during the reporting period[144] - The board of directors and supervisory board operate independently, ensuring compliance with legal and regulatory requirements[143] - There were no instances of non-compliance in information disclosure during the reporting period[144] - The company has established a robust governance structure that aligns with the requirements of the Company Law and Securities Law[142] Financial Management - The company has a complete and independent financial management system, with dedicated accounting personnel and independent decision-making capabilities[146] - The cash dividend accounted for 100% of the distributable profit of RMB 1,665,011,825.85[191] - The company has no stock incentive plans or employee stock ownership plans in place during the reporting period[192] - The internal control self-assessment report indicated that all units included in the evaluation accounted for 100% of the consolidated financial statement assets[197] Challenges and Risks - The company faces risks related to fluctuations in vitamin D3 prices, which significantly impact revenue due to the high proportion of related products[135] - The company is exposed to project investment risks associated with the construction of the Jinxi Technology Park, which may affect strategic implementation and operational scale[135] - The company anticipates challenges in attracting and retaining high-quality talent necessary for its growth strategy[135] - The company may face adverse effects on sales if certain products are included in national centralized procurement and are not selected[137]

Revenue and Profit - Revenue for Q3 2021 was ¥106,084,487.92, a decrease of 26.95% compared to the same period last year[7] - Net profit attributable to shareholders was ¥40,729,866.67, down 36.18% year-over-year[7] - Net profit excluding non-recurring gains and losses was ¥38,674,059.36, a decrease of 31.56% compared to the previous year[7] - Total operating revenue for the third quarter was ¥455,723,293.94, a decrease of 7.06% compared to ¥490,403,590.51 in the same period last year[33] - Net profit for the period was ¥276,307,586.34, representing an increase of 22.09% from ¥226,353,727.11 in the previous year[36] - The total comprehensive income attributable to the parent company's owners was CNY 276,307,586.34, an increase from CNY 226,353,727.11 in the previous period, representing a growth of approximately 22.1%[39] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥3,623,068,855.75, an increase of 5.78% from the end of the previous year[9] - Total assets reached ¥3,623,068,855.75, an increase of 5.78% compared to ¥3,425,191,470.28 at the end of the previous year[32] - Total liabilities decreased to ¥492,913,679.53, down 4.35% from ¥515,380,606.94 year-on-year[32] - The company's equity attributable to shareholders increased to ¥3,130,155,176.22, up 7.57% from ¥2,909,810,863.34 in the previous year[32] Cash Flow - Cash flow from operating activities for the year-to-date was ¥172,075,303.56, down 36.36% compared to the same period last year[7] - Cash inflow from operating activities totaled CNY 644,906,458.61, compared to CNY 612,232,936.86 in the previous period, indicating an increase of approximately 5.3%[40] - The net cash flow from operating activities was CNY 172,075,303.56, down from CNY 270,391,116.83, showing a decrease of about 36.4%[43] - Cash inflow from investment activities was CNY 502,247,721.20, up from CNY 405,790,587.67, marking an increase of approximately 23.8%[43] - The net cash flow from investment activities was negative at CNY -378,451,716.74, an improvement from CNY -428,469,817.15 in the previous period, indicating a reduction in losses of about 11.7%[43] - Cash and cash equivalents at the end of the period were CNY 901,266,660.52, down from CNY 1,178,844,213.62, a decrease of approximately 23.5%[43] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,194, with the largest shareholder, Zhejiang Xiangyun Technology Co., Ltd., holding 26.20% of shares, totaling 144,376,377 shares[15] - The largest shareholder, Zhejiang Xiangyun Technology Co., Ltd., has pledged 97,570,000 shares, indicating a significant level of collateralization[15] - The company reported a total of 92,010,707 restricted shares at the beginning of the period, with 89,465,179 shares released during the period, resulting in 6,969,562 restricted shares remaining[21] - The total number of restricted shares held by other shareholders amounts to 32,063,837, with a significant portion being executive lock-up shares[21] Expenses and Investments - Total operating costs decreased to ¥245,771,846.00, down 6.69% from ¥263,414,345.02 year-on-year[33] - Research and development expenses increased to ¥27,233,332.31, up 9.03% from ¥24,859,986.83 year-on-year[36] - The company reported a financial income of ¥22,675,992.68, an increase from ¥14,861,108.09 in the previous year[36] - The company experienced a 270.81% increase in financial income due to higher bank deposit interest income compared to the previous year[13] - The company reported a significant increase in construction in progress, totaling ¥1,314,611,423.82, up 32.82% from the previous year[11] - The company has a total of 1,314,611,423.82 in construction in progress, up from 989,765,553.50 in the previous year, showing an increase of approximately 32.83%[25] Cash Management - The company’s cash and cash equivalents as of September 30, 2021, amount to ¥901,266,660.52, a decrease from ¥1,158,650,345.38 at the end of 2020, representing a decline of approximately 22.14%[25] - The total current assets decreased from ¥1,771,836,559.96 at the end of 2020 to ¥1,570,596,412.65, reflecting a reduction of about 11.34%[25] - Inventory increased from ¥306,800,708.88 at the end of 2020 to ¥350,377,187.23, indicating a growth of approximately 14.19%[25] - The company paid CNY 83,608,124.50 in taxes, significantly higher than CNY 41,071,882.64 in the previous period, reflecting an increase of about 103.5%[43] - The company reported cash outflows from financing activities totaling CNY 310,329,467.90, compared to CNY 381,465,050.77 in the previous period, a decrease of approximately 18.6%[43] Financial Reporting - The company did not require adjustments to the beginning balance sheet items under the new leasing standards, indicating stability in financial reporting[44]

Financial Performance - The company's operating revenue for the reporting period was ¥349,638,806.02, an increase of 1.29% compared to the same period last year[33]. - The net profit attributable to shareholders was ¥235,577,719.67, representing a significant increase of 44.94% year-over-year[33]. - The net profit after deducting non-recurring gains and losses was ¥144,328,148.85, up by 4.46% from the previous year[33]. - The net cash flow from operating activities decreased by 37.30% to ¥126,014,817.85 compared to the same period last year[33]. - The total assets at the end of the reporting period were ¥3,507,539,168.49, reflecting a growth of 2.40% from the end of the previous year[33]. - The net assets attributable to shareholders increased by 6.17% to ¥3,089,425,309.55 compared to the end of the previous year[33]. - The gross profit margin for vitamin D3 and similar products was 67.58%, a decrease of 4.33% compared to the previous year[58]. - The company's financial expenses increased by 154.70% to -¥11,443,115.80, primarily due to increased interest income from bank deposits[55]. - The cash and cash equivalents decreased by 134.51% to -¥29,902,605.03 from an increase of ¥86,649,874.28 in the previous year[58]. Investment and Development - The company plans to invest in the Jinxi Technology Park project, which is expected to enhance strategic implementation and expand operational scale, although there are uncertainties regarding construction progress and costs[6]. - The company is focusing on the development of new products and technologies, particularly in the field of vitamin D3 derivatives[20]. - The company aims to develop full-active vitamin D3 and similar products to enter the pharmaceutical and health product sectors in the future[50]. - The company has established a clear development strategy to build a complete vitamin D3 upstream and downstream industrial chain, achieving a leading position in the industry[50]. - The company is exploring potential mergers and acquisitions to enhance its market position and expand its product offerings[20]. Talent and Human Resources - The company emphasizes the need for high-quality talent in R&D, production, sales, and management, which requires substantial investment and poses a risk of personnel stability[7]. - The company faces risks related to the price fluctuations of feed-grade vitamin D3, which significantly impact revenue[88]. - The company has not sold any significant assets or equity during the reporting period[84]. Shareholder and Equity Information - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves for the reporting period[11]. - The total number of shares outstanding is 551,007,557, with 83.30% being unrestricted shares[137]. - The company repurchased 7,674,790 shares, representing 1.39% of the total share capital[148]. - The largest shareholder, Zhejiang Xiangyun Technology Co., Ltd., has pledged 98,570,000 shares[145]. - The total number of ordinary shareholders at the end of the reporting period was 23,111, with a shareholding ratio of 5%[145]. Financial Management and Reporting - The company is committed to ensuring the accuracy and completeness of its financial reports, with key personnel affirming the integrity of the data presented[5]. - The half-year financial report was not audited[109]. - The company maintained a tax credit rating of A-level, fulfilling its social responsibilities effectively[103]. - There were no significant environmental protection issues reported during the period, and the company was recognized as a leading enterprise in environmental protection in Zhejiang Province[102]. Market and Operational Risks - The company is actively monitoring market trends and price fluctuations in the vitamin D3 sector to mitigate risks associated with revenue[6]. - The construction of the Jinxiketechnology park project is crucial for the company's strategic development but carries uncertainties in progress and costs[88]. - The company has established long-term stable strategic partnerships with internationally renowned manufacturers and distributors, enhancing its market channel advantages[54].

Financial Performance - The company's operating revenue for Q1 2021 was ¥158,982,505.22, representing a 17.39% increase compared to ¥135,433,235.78 in the same period last year[8] - Net profit attributable to shareholders for Q1 2021 reached ¥91,420,363.82, a significant increase of 48.85% from ¥61,418,396.61 in the previous year[8] - The net profit after deducting non-recurring gains and losses was ¥68,852,669.27, marking a 65.56% increase from ¥41,587,644.62 year-on-year[8] - Basic and diluted earnings per share for Q1 2021 were both ¥0.17, reflecting a 30.77% increase from ¥0.13 in the previous year[8] - The company reported a significant increase in tax expenses by 47.21% to ¥15,198,400.42 from ¥10,324,308.08, driven by higher total profit[26] - The company reported a net profit of CNY 1,428,005,020.94, up from CNY 1,336,584,657.12, reflecting an increase of approximately 7%[87] Cash Flow - The net cash flow from operating activities was ¥77,397,843.98, up 9.32% from ¥70,800,373.59 in the same quarter last year[8] - Cash flow from financing activities showed a net outflow of ¥51,764,416.66, a decrease of 382.90% compared to the previous period[26] - The net increase in cash and cash equivalents was a decrease of 149.89% to -¥81,540,848.95 from -¥32,630,440.62, primarily due to loan repayments[26] - Operating cash inflow for the current period reached ¥415,485,372.30, a significant increase from ¥150,864,932.56 in the previous period[115] - Net cash flow from operating activities was ¥126,663,917.65, compared to a negative cash flow of -¥26,980,473.78 in the previous period[115] - Total cash and cash equivalents at the end of the period were ¥1,077,109,496.43, down from ¥1,158,650,345.38 at the beginning of the period[113] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,396,270,569.44, a decrease of 0.84% from ¥3,425,191,470.28 at the end of the previous year[8] - The company's total current liabilities decreased to CNY 307,655,507.94 from CNY 404,873,605.68, a decline of about 24%[84] - Non-current liabilities also decreased to CNY 87,383,834.34 from CNY 110,507,001.26, representing a reduction of approximately 21%[84] - Total liabilities increased to ¥319,453,671.16 from ¥312,278,031.30, representing a growth of approximately 2.0%[94] Shareholder Information - Net assets attributable to shareholders increased to ¥3,001,231,227.16, up 3.14% from ¥2,909,810,863.34 at the end of the previous year[8] - The total number of ordinary shareholders at the end of the reporting period was 23,142, with the largest shareholder holding 26.20% of the shares[12] Expenses - The company's sales expenses increased by 70.12% to ¥3,145,517.61 from ¥1,849,049.29, attributed to higher sample and advertising costs[23] - Research and development expenses decreased by 36.98% to ¥5,086,875.50 from ¥8,071,303.70, mainly due to reduced material costs for R&D[23] - Total operating costs decreased to ¥78,489,139.00 from ¥86,032,208.99, reflecting a reduction of about 8.5%[97] Investment and Projects - The construction of the Jinxi Technology Park project is progressing steadily, with plans to complete the eastern area by the end of 2021[29] - The core premix project has a total investment of 12,550 million yuan, with 77.72% of the investment completed[33] - The annual production project for 1,200 tons of lanolin cholesterol has reached 51.26% of its investment completion[33] Risks and Challenges - The company faces risks related to project investment, including uncertainties in construction progress and costs[29] - The company has a high demand for skilled professionals in R&D, production, and management, which poses a risk in talent acquisition and retention[29] - The revenue from Vitamin D3 and similar products accounts for a significant portion of total revenue, making the company vulnerable to price fluctuations in these products[29]

Financial Performance - The company's operating revenue for 2020 was ¥614,894,440.85, a decrease of 14.41% compared to ¥718,384,535.71 in 2019[27]. - The net profit attributable to shareholders for 2020 was ¥272,264,655.97, down 20.79% from ¥343,706,532.78 in 2019[27]. - The net profit after deducting non-recurring gains and losses was ¥224,528,311.79, a decline of 31.85% from ¥329,475,838.43 in 2019[27]. - The net cash flow from operating activities increased by 13.65% to ¥416,571,982.43 in 2020, compared to ¥366,536,248.37 in 2019[27]. - The total assets at the end of 2020 were ¥3,425,191,470.28, reflecting a 64.70% increase from ¥2,079,607,778.24 at the end of 2019[27]. - The net assets attributable to shareholders at the end of 2020 were ¥2,909,810,863.34, up 66.94% from ¥1,743,033,011.20 at the end of 2019[27]. - The basic earnings per share for 2020 was ¥0.54, a decrease of 25.00% from ¥0.72 in 2019[27]. - The diluted earnings per share for 2020 was also ¥0.54, down 25.00% from ¥0.72 in 2019[27]. - The company reported a government subsidy of ¥49,274,004.09 in 2020, significantly higher than ¥6,128,657.79 in 2019[33]. - In 2020, the company achieved operating revenue of 614.89 million yuan, a decrease of 14.41% compared to the previous year[55]. - The net profit attributable to shareholders was 272.26 million yuan, down 20.79% year-on-year[55]. Investment and Projects - The company is investing in the Jinxi Technology Park project, which is expected to enhance its strategic development and operational scale, although there are uncertainties regarding construction progress and costs[6]. - The company acknowledges the risks associated with project investments, including potential changes in engineering quality and investment costs[6]. - The company has committed to invest CNY 12,550 million in the core premix project, with a cumulative investment of CNY 77.72 million by the end of the reporting period[88]. - The annual production project of 4,000 tons of environmentally friendly rodenticide has a total investment commitment of CNY 15,500 million, with CNY 2,091.9 million invested to date[88]. - The annual production of 180 tons of 7-dehydrocholesterol project has an adjusted total investment of CNY 8,000 million, with a cumulative investment of CNY 9,144.67 million, achieving 114.31% of the investment progress[88]. - The company plans to relocate its production base to Jinhua Economic and Technological Development Zone to improve operational efficiency and reduce costs[94]. - The company has approved the replacement of self-raised funds with raised funds for several projects, totaling CNY 215,944.55 million[95]. Talent and Human Resources - The company faces a substantial increase in demand for high-quality talent in R&D, production, sales, and management, necessitating significant investments in human capital[7]. - The company has implemented a talent strategy focused on employee development and compliance with labor laws[166]. Market Strategy and Product Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[6]. - The company aims to enhance its market position in the vitamin D3 sector by integrating production and market strategies, targeting a steady increase in market prices[107]. - The company has completed the layout of the entire vitamin D3 industry chain, focusing on innovation and market expansion[106]. - The company has established a clear full industry chain advantage, integrating upstream and downstream operations in the vitamin D3 sector[47]. - The company has a leading production technology advantage, with its processes for vitamin D3 and NF-grade cholesterol being at the forefront of the industry[48]. Shareholder and Dividend Information - The profit distribution plan approved by the board proposes a cash dividend of 1.03 CNY per 10 shares, based on a total of 543,332,767 shares[10]. - The company’s cash dividend distribution policy aligns with its articles of association and shareholder resolutions, ensuring transparency and compliance[111]. - The company has committed to distributing cash dividends if there are no major investment plans or significant cash expenditures, ensuring that the cash dividends will not be less than the distributable profits for the year[120]. - The company’s cash dividends for 2020 were 20.55% of the net profit attributable to ordinary shareholders, with a total cash dividend of RMB 55,963,275.00[116]. - The company’s cash dividend distribution in 2019 was 29.10% of the net profit attributable to ordinary shareholders, with a total cash dividend of RMB 100,001,821.18[116]. Governance and Compliance - The company is committed to ensuring the accuracy and completeness of its financial reports, with all board members present for the review[6]. - The company has established a robust governance structure to manage risks related to human resources and project investments[6]. - The company has established measures to ensure the fulfillment of public commitments by its controlling shareholders and management, including penalties for non-compliance[123]. - The company has committed to repurchasing shares if there are false records or misleading statements in the prospectus, ensuring compliance with regulatory requirements[120]. Cash Flow and Financing - The cash flow from operating activities was CNY 416.57 million, an increase of 13.65% year-on-year, mainly due to higher government subsidies and tax refunds[60]. - The company completed a private placement raising CNY 909.4 million, which will be used for expanding production capacity in various projects[56]. - The company’s cash and cash equivalents at the end of 2020 were CNY 1.16 billion, a 129.10% increase from the beginning of the year[60]. - The company’s cash flow from financing activities increased by 861.69% to ¥831,740,316.69, primarily due to a non-public offering of 71,719,242 shares, raising ¥909,399,988.56[79]. Customer and Supplier Concentration - Total sales from the top five customers amounted to ¥303,518,707.95, accounting for 49.35% of the annual total sales[70]. - The largest customer contributed ¥142,221,670.34, representing 23.13% of the annual total sales[70]. - Total purchases from the top five suppliers reached ¥131,930,683.62, which is 57.41% of the annual total purchases[73]. - The largest supplier accounted for ¥44,491,980.00, or 19.36% of the annual total purchases[73].

Financial Performance - Total revenue for Q1 2020 was ¥135,433,235.78, a decrease of 42.78% compared to ¥236,707,439.76 in the same period last year[8] - Net profit attributable to shareholders was ¥61,418,396.61, down 52.46% from ¥129,183,125.11 year-on-year[8] - Net profit excluding non-recurring gains and losses was ¥41,587,644.62, a decline of 67.24% compared to ¥126,957,907.96 in the previous year[8] - Basic earnings per share decreased to ¥0.13, down 51.85% from ¥0.27 year-on-year[8] - Cash received from sales of goods decreased by 54.43% to ¥115,876,132.67, reflecting a decline in operating income[21] - The company's revenue for the current period decreased by 42.78% to ¥135,433,235.78, mainly due to a decline in sales volume and average selling price of Vitamin D3 caused by the COVID-19 pandemic[20] - Total operating revenue for the current period is ¥135,433,235.78, a decrease of 42.7% compared to ¥236,707,439.76 in the previous period[64] - Net profit for the current period is ¥61,418,396.61, down 52.4% from ¥129,183,125.11 in the previous period[71] - The company recorded other income of ¥23,282,572.97, a significant increase from ¥338,328.94 in the previous period[67] Cash Flow - Net cash flow from operating activities was ¥70,800,373.59, down 56.42% from ¥162,458,349.62 in the same period last year[8] - Operating cash flow for the current period was -26,980,473.78 CNY, a significant decrease from 200,657,653.53 CNY in the previous period[85] - Total cash inflow from operating activities was 150,864,932.56 CNY, down from 345,255,039.82 CNY year-over-year[85] - Cash outflow from operating activities increased to 177,845,406.34 CNY compared to 144,597,386.29 CNY in the previous period[85] - Cash and cash equivalents decreased to ¥473,111,906.64 from ¥505,742,347.26, representing a decline of 6.5%[48] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,154,734,826.70, an increase of 3.61% from ¥2,079,607,778.24 at the end of the previous year[8] - Current liabilities totaled ¥346,719,043.51, an increase of 4.1% from ¥332,882,613.29[54] - Total liabilities amounted to ¥350,283,418.89, up 4.1% from ¥336,574,767.04[54] - The company's equity attributable to shareholders increased to ¥1,804,451,407.81, up 3.5% from ¥1,743,033,011.20[57] Investments and Projects - The company plans to expedite the construction of the Jinxi Technology Park project, aiming for completion and production in the first half of 2020 despite delays caused by the pandemic[25] - The construction of the Jinxi Technology Park project poses investment risks, including uncertainties in construction progress and costs[26] - The company has adjusted the implementation location of certain projects from Dongyang to Jinhua Economic and Technological Development Zone[37] - The company has temporarily suspended the implementation of the "Core Premix Project" and "Annual Production of 4,000 Tons of Environmentally Friendly Rodenticide Project" due to a board resolution[42] Government Support and Subsidies - Government subsidies recognized in the current period amounted to ¥23,282,572.97[8] - Other income increased by 6781.64% to ¥23,282,572.97, mainly due to an increase in government subsidies received[20] Risks and Challenges - The company faces risks related to fluctuations in Vitamin D3 prices, which significantly impact revenue due to the high proportion of related product sales[25] - The company is facing risks related to the integration of management and human resources due to the increased demand for high-quality talent[29] Shareholder Information - The top shareholder, Zhejiang Xiangyun Technology Co., Ltd., held 35.87% of shares, amounting to 171,926,877 shares[12] Fundraising and Utilization - The company plans to raise up to RMB 106,900 million through a private placement to support seven projects, including the production of 1,200 tons of lanolin cholesterol and 8,000 tons of refined lanolin[30] - As of the report date, the total amount of raised funds is RMB 40,670.72 million, with RMB 3,471.03 million invested in the current quarter[33] - Cumulative changes in the use of raised funds amount to RMB 16,350 million, representing 40.20% of the total raised funds[33] - The cumulative amount of raised funds utilized by the end of the reporting period is RMB 36,751.92 million[33] - The company has not reported any issues regarding the use and disclosure of raised funds[42]

证券代码：300401 证券简称：花园生物 公告编号：2019-055 浙江花园生物高科股份有限公司 关于参加浙江辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，浙江花园生物高科股份有限公司（以下简称 "公司"）将参加由中国证监会浙江证监局指导、浙江上市公司协会与深圳市全景网络 有限公司共同举办的浙江辖区上市公司投资者网上集体接待日活动，现将有关事项公告 如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网上平台 举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net）参与公司本次 投资者网上接待日活动，网上互动交 流时间为2019年11月5日（星期 二）下午 15:30-17:00。届时公司董事常务副总经理刘建刚先生、董事副总经理董事会秘书喻铨 衡先生、财务总监吴春华先生将采用网络远程方式，与投资者就公司治理、发展战略、 经营情况、可持续发展等投资者关注的问题进行沟通。欢迎广大投资者积极参与。 特此公告。 浙江花园生物高科股份有限公司董事会 ...

Financial Performance - Total operating revenue for the first half of 2019 was CNY 418,217,299.22, representing a 30.36% increase compared to CNY 320,806,232.80 in the same period last year[28]. - Net profit attributable to shareholders of the listed company reached CNY 229,673,653.04, a 49.97% increase from CNY 153,143,898.51 year-on-year[28]. - Net profit after deducting non-recurring gains and losses was CNY 221,563,777.18, up 51.63% from CNY 146,118,223.48 in the previous year[28]. - Net cash flow from operating activities was CNY 201,198,542.26, reflecting a 52.12% increase compared to CNY 132,259,785.07 in the same period last year[28]. - Basic earnings per share increased to CNY 0.48, a 50.00% rise from CNY 0.32 in the previous year[28]. - The company reported a significant increase in cash and cash equivalents, with a net increase of RMB 206,594,664.69, a 163.42% improvement compared to the previous year[56]. - The gross profit margin for Vitamin D3 and similar products was 83.70%, with a year-on-year increase of 4.14%[56]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,894,579,196.42, a 15.08% increase from CNY 1,646,296,555.26 at the end of the previous year[28]. - Net assets attributable to shareholders of the listed company were CNY 1,729,051,954.35, up 10.72% from CNY 1,561,685,782.26 at the end of the previous year[28]. - Total liabilities increased to ¥165,527,242.07 from ¥84,610,773.00, showing a significant rise of approximately 95.5%[200]. - Current assets rose to ¥1,107,390,857.37 from ¥967,525,178.83, reflecting an increase of about 14.5%[200]. - Non-current assets totaled ¥787,188,339.05, compared to ¥678,771,376.43, marking a growth of around 15.9%[200]. Investment and Projects - The company is investing in the Jinxi Technology Park project, which is expected to influence its strategic development and operational scale[6]. - The construction of the Jinxi Technology Park project is ongoing, although progress has been affected by weather conditions[51]. - The total committed investment for the core premix project is CNY 12,550,000, with 100% investment progress achieved[63]. - The company plans to postpone investments in the core premix and environmentally friendly rodenticide projects due to market conditions and risks of not achieving expected benefits[98]. - The remaining funds originally allocated for the postponed projects will be redirected to the 7-dehydrocholesterol and feed-grade VD3 oil projects, which have more urgent funding needs[98]. Market and Competition - The main business focus is on the complete vitamin D3 industry chain, with key products including cholesterol, vitamin D3, and 25-hydroxyvitamin D3[39]. - The company has a clear competitive advantage in the vitamin D3 industry, being a leading manufacturer with a comprehensive product range[46]. - The company faces risks related to the price fluctuations of Vitamin D3, which significantly impact its revenue[6]. - The company’s vitamin D3 product sales volume increased year-on-year, driving profit growth during the reporting period[41]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[9]. - The first temporary shareholders' meeting in 2019 had an investor participation rate of 45.17%[112]. - The company has committed to distributing at least 20% of its distributable profits in cash if no major investment plans arise[116]. - The company has made long-term commitments to avoid competition with its subsidiaries and ensure compliance with regulatory requirements[116]. - The company has established measures to ensure the fulfillment of public commitments by its controlling shareholders and senior management[120]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[146]. - Wastewater discharge monitoring facilities are installed and connected to environmental authorities for real-time monitoring[151]. - The company has complied with environmental impact assessment regulations for all construction projects[151]. - The company has implemented emergency response plans for environmental incidents and registered them with authorities[151]. Miscellaneous - The company has not sold any significant assets during the reporting period[105]. - There were no instances of entrusted financial management, derivative investments, or entrusted loans during the reporting period[102][103][104]. - The company has not experienced any major litigation or arbitration matters during the reporting period[125]. - The company has not engaged in any poverty alleviation initiatives during the reporting period[151].

Financial Performance - Total revenue for Q1 2019 was CNY 236,707,439.76, representing a 0.51% increase compared to CNY 235,500,525.62 in the same period last year[8] - Net profit attributable to shareholders was CNY 129,183,125.11, up 5.98% from CNY 121,898,566.96 year-on-year[8] - Basic and diluted earnings per share rose to CNY 0.27, an increase of 8.00% from CNY 0.25 in the same period last year[8] - Operating profit for the current period was ¥151,335,656.12, an increase of 7.92% from ¥141,074,566.57 in the previous period[63] - Net profit for the current period was ¥129,183,125.11, up 5.25% from ¥121,898,566.96 in the previous period[66] Cash Flow - Net cash flow from operating activities increased by 66.41% to CNY 162,458,349.62, compared to CNY 97,624,376.92 in the previous year[8] - Cash flow from operating activities increased to ¥162,458,349.62, up from ¥97,624,376.92 in the previous period, reflecting improved operational efficiency[75] - Cash inflow from operating activities totaled ¥345,255,039.82, compared to ¥299,291,997.08 in the previous period, reflecting an increase of approximately 15.4%[84] - The net cash flow from operating activities for the current period is ¥200,657,653.53, a decrease from ¥209,456,384.65 in the previous period[84] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,769,472,032.40, reflecting a 7.48% increase from CNY 1,646,296,555.26 at the end of the previous year[8] - Total current assets increased to ¥1,078,041,607.04 from ¥967,525,178.83, representing a growth of approximately 11.4%[46] - Total current liabilities decreased to ¥75,844,085.60 from ¥81,760,404.63, a decline of about 7.4%[49] - Total liabilities amounted to ¥78,603,125.03, down from ¥84,610,773.00, indicating a decrease of approximately 7.1%[49] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,037[12] - The largest shareholder, Zhejiang Xiangyun Technology Co., Ltd., held 36.10% of the shares, amounting to 172,999,527 shares[12] - Net assets attributable to shareholders increased by 8.27% to CNY 1,690,868,907.37 from CNY 1,561,685,782.26 at the end of the previous year[8] Research and Development - Research and development expenses surged by 190.47% to ¥8,465,123.47, reflecting increased investment in technology reserves for future development[22] - Research and development expenses increased significantly to ¥8,465,123.47, up 200.00% from ¥2,914,262.35 in the previous period[63] Investment Activities - The total amount of raised funds is 40,670.72 million yuan, with 385.28 million yuan invested in the current quarter and a cumulative investment of 6,681.67 million yuan[31] - The core premix project has a total investment of 12,550 million yuan, with 8,280 million yuan invested, achieving 36.07% of the expected progress[31] - The company has not encountered any significant changes in the feasibility of its investment projects or any major deviations from planned progress or expected benefits[34] Operational Management - The company adhered to its 2019 annual business plan, effectively advancing production and operational management tasks[26] - The construction of the Jinxi Technology Park project is crucial for the company's strategic development and operational scale, but it faces uncertainties in progress and implementation[29] Other Financial Metrics - Other receivables increased by 146.71% to ¥1,539,753.89, mainly due to higher deposits and guarantees[22] - The company’s total liabilities decreased by 61.39% in employee compensation, attributed to the payment of last year's salary adjustments and bonuses[22] - The company reported a 39.49% increase in cash from operating activities, driven by higher cash receipts from sales[22]

Financial Performance - Operating revenue for the period reached CNY 154,981,647.10, a 100.79% increase year-on-year[8] - Net profit attributable to shareholders increased by 156.06% to CNY 71,601,524.89 compared to the same period last year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 146.70% to CNY 64,361,005.89 compared to the same period last year[8] - Basic earnings per share rose by 150.00% to CNY 0.15[8] - The weighted average return on equity increased to 4.96%, up 1.60 percentage points from the previous year[8] - Net profit rose by 117.88% to ¥224,745,423.40, attributed to higher operating revenue and improved product gross margins[18] - Total profit increased by 117.12% to ¥261,421,254.75, driven by rising operating revenue and product gross margin improvements[18] - Total operating revenue for the third quarter reached ¥154,981,647.10, a significant increase from ¥77,187,458.57 in the same period last year, representing a growth of 100.0%[35] - Net profit for the period was ¥71,601,524.89, compared to ¥27,962,875.94 in the previous year, marking an increase of 156.5%[37] - The company reported an operating profit of ¥83,180,263.42, compared to ¥32,109,503.28 in the previous year, an increase of 158.0%[37] - The company reported a total profit of CNY 72,717,004.56 for the third quarter, compared to CNY 22,290,260.30 in the previous year, indicating an increase of approximately 226.5%[41] Assets and Liabilities - Total assets increased by 13.95% to CNY 1,589,478,052.51 compared to the end of the previous year[8] - Net assets attributable to shareholders increased by 15.45% to CNY 1,479,022,558.67 compared to the end of the previous year[8] - The company's total assets reached ¥1,589,478,052.51, up from ¥1,394,834,071.76 at the beginning of the period[30] - The total liabilities decreased slightly to ¥110,455,493.84 from ¥113,716,790.85, indicating improved financial stability[30] - The company's equity attributable to shareholders increased to ¥1,479,022,558.67 from ¥1,281,117,280.91, reflecting strong retained earnings growth[30] - Current liabilities rose to ¥256,913,792.18, up from ¥95,610,638.65, indicating an increase of 168.5%[33] Cash Flow - The net cash flow from operating activities for the year-to-date reached CNY 168,562,463.96, an increase of 36.17%[8] - Cash received from sales and services increased by 29.53% to ¥451,289,019.32 compared to ¥348,395,304.60 in the same period last year[19] - Cash inflow from investment activities surged by 282.54% to ¥1,571,760,036.10, primarily due to an increase in matured financial products[19] - Cash outflow for investment activities increased by 298.54% to ¥1,856,176,478.34, mainly due to higher purchases of financial products[19] - The net cash flow from financing activities showed a significant decline of 783.66%, resulting in a net outflow of ¥31,674,365.18, attributed to increased cash dividends distributed[19] - Cash flow from operating activities generated a net amount of CNY 168,562,463.96, up from CNY 123,786,816.78 year-over-year, reflecting a growth of approximately 36.2%[50] - The company’s cash flow from financing activities resulted in a net outflow of -CNY 31,674,365.18, compared to -CNY 3,584,437.50 in the previous year[52] Research and Development - Research and development expenses surged by 156.92% to ¥16,537,979.55, reflecting increased investment in new products and processes[17] - Research and development expenses for the quarter were ¥7,540,518.64, compared to ¥4,389,041.50 in the previous year, an increase of 71.8%[35] - Research and development expenses increased to CNY 16,537,979.55 from CNY 6,436,910.88, reflecting a rise of about 157.5%[44] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,417[11] - The total number of restricted shares increased to 46,202,893, with a total of 28,050,367 shares added during the period[14] Government Subsidies - The company received government subsidies amounting to CNY 7,151,708.22 during the reporting period[9] - Other income increased by 85.05% to ¥7,151,708.22, mainly due to higher government subsidies received[17] Taxation - The company reported a 146.53% increase in taxes and surcharges to ¥7,169,227.21, resulting from increased export tax exemptions[17] - The company paid CNY 50,754,377.09 in taxes during the quarter, compared to CNY 24,738,807.12 in the previous year, indicating an increase of about 105.5%[50]